Mui Kow - Haw Par Executive
HAWPF Stock | USD 8.35 0.00 0.00% |
Executive
Mr. Kow Mui Lick is Senior Manager Quality Regulatory Affairs of Healthcare of Haw Par Corporation Ltd. He joined Haw Par Healthcare in 1991 as QCLaboratory Manager and promoted to Senior Manager in 2007. Appointed to present position in 2011. Holds a BS from the University of Singapore.
Phone | 65 6337 9102 |
Web | https://www.hawpar.com |
Haw Par Management Efficiency
Haw Par's management efficiency ratios could be used to measure how well Haw Par manages its routine affairs as well as how well it operates its assets and liabilities.Haw Par has accumulated 12.92 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Haw Par has a current ratio of 7.37, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Haw Par until it has trouble settling it off, either with new capital or with free cash flow. So, Haw Par's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Haw Par sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Haw to invest in growth at high rates of return. When we think about Haw Par's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | EXECUTIVE Age | ||
Hani Abouhalka | Johnson Johnson | N/A | |
Klaus Moosmayer | Novartis AG ADR | 56 | |
Vittorio Nisita | Organon Co | 55 | |
Celine Martin | Johnson Johnson | N/A | |
Darryl MD | Amgen Inc | N/A | |
David MD | Amgen Inc | 61 | |
Donald Zakrowski | Eli Lilly and | N/A | |
Matthew Busch | Amgen Inc | 50 | |
Michael Bodner | Johnson Johnson | N/A | |
David Redfern | GlaxoSmithKline PLC ADR | 58 | |
Rudolf Ertl | Gilead Sciences | 78 | |
Peter Dannenbaum | Merck Company | N/A | |
Nancy Grygiel | Amgen Inc | 56 | |
Jessica Moore | Johnson Johnson | N/A | |
Jennifer Halchak | Organon Co | N/A | |
Annette Doherty | Pfizer Inc | N/A | |
Kimberly Jablonski | Bristol Myers Squibb | N/A | |
Catherine Adams | Bristol Myers Squibb | 54 | |
Thomas MD | AbbVie Inc | 62 | |
Elizabeth JD | Johnson Johnson | 53 | |
Dalton III | Merck Company | 57 |
Management Performance
Return On Equity | 0.0424 | |||
Return On Asset | 0.0063 |
Haw Par Leadership Team
Elected by the shareholders, the Haw Par's board of directors comprises two types of representatives: Haw Par inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haw. The board's role is to monitor Haw Par's management team and ensure that shareholders' interests are well served. Haw Par's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haw Par's outside directors are responsible for providing unbiased perspectives on the board's policies.
Meng Kwek, Regional General Manager of Underwater World Singapore Pte Ltd / Haw Par Leisure Pte Ltd | ||
Kun Chiew, Group Sec | ||
Say Chow, Group Finance Controller | ||
Ee Wee, CEO and President Director, Member of Investment Committee, CEO of Haw Par Healthcare Limited and Acting President of Haw Par Healthcare Limited | ||
Mui Kow, Senior Manager-Quality & Regulatory Affairs of Healthcare | ||
Tang Lee, Mang Communications | ||
Tang Chow, Human Director | ||
Brian Loo, Group Mang |
Haw Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Haw Par a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0424 | |||
Return On Asset | 0.0063 | |||
Profit Margin | 0.79 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | (701.58 M) | |||
Shares Outstanding | 221.37 M | |||
Shares Owned By Insiders | 36.98 % | |||
Shares Owned By Institutions | 32.30 % | |||
Price To Earning | 15.92 X | |||
Price To Book | 0.65 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Haw Pink Sheet
Haw Par financial ratios help investors to determine whether Haw Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Haw with respect to the benefits of owning Haw Par security.